Finished Research Projects

Truncate-TB Study

Two-Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis

BDB-001

A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II/III

Solidarity

International Clinical Trial of adjuvant drugs for COVID-19 in hospital patients receiving local standard care – Solidarity Trial

AVIMAC Study

A Randomized, Open label, Controlled Study to Evaluate Efficacy and Tolerability of the Administration of AVIMAC as Adjuvant Treatment in Mild or Moderate COVID-19 Patients who Receive the Standard Treatment

Stem Cell

Application of mesenchymal stem cells from the umbilical cord as adjuvant therapy in moderately severe COVID-19 pneumonia patients

Secretome

Effectiveness and Safety Profile of Mesenchymal Stem Cell Secretome as Therapy for Severe Cases of COVID-19

PrevTB

Prevalence of Tuberculosis Patients at Persahabatan General Hospital During the Corona Virus Desease-19 Pandemic

Remdesivir (Retros)

Evaluation of Safety and Effectiveness of Remdesivir in Treating COVID-19 Patients After EUA (Emergency Use Authorization)

ACT-HIV

A randomized double blind placebo controlled trial of adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT-HIV Trial)

Nontuberculous
Mycobacterium (NTM)

Prevalence and Characteristics of Patients with Nontuberculous Mycobacteria (NTM) Infections

Remdesivir (Retros)

Evaluation of Safety and Effectiveness of Remdesivir in Treating COVID-19 Patients After EUA (Emergency Use Authorization)

A Randomized, Double-Blind, Controlled Trial to Evaluate the Efficacy of Remdesivir Administration for 5 days and 10 days in Moderate and Severe COVID-19 Inpatients

Remdesivir (ClinTrial)

ImmuneMed

A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients